NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
Clinical Trials
6 trialsNCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing
NCT03126643 2021-11-29
Expanded Access to Nivolumab (Opdivo)
Bristol-Myers Squibb
Approved for marketing
NCT03079687 2017-10-25
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AstraZeneca
Approved for marketing
NCT01606982 2017-02-17
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Approved for marketing